AnaptysBio, Inc. (NASDAQ:ANAB) Insider Sells $58,005.00 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

AnaptysBio Price Performance

NASDAQ ANAB traded down $0.69 during trading on Tuesday, reaching $34.88. 233,203 shares of the company’s stock were exchanged, compared to its average volume of 328,526. The business has a 50 day moving average price of $35.79 and a 200-day moving average price of $27.95. The stock has a market capitalization of $952.89 million, a P/E ratio of -5.68 and a beta of -0.29. AnaptysBio, Inc. has a fifty-two week low of $13.36 and a fifty-two week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The business had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. On average, analysts forecast that AnaptysBio, Inc. will post -6.84 earnings per share for the current year.

Hedge Funds Weigh In On AnaptysBio

Institutional investors have recently bought and sold shares of the business. Great Point Partners LLC grew its position in shares of AnaptysBio by 9.2% in the fourth quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock valued at $20,927,000 after purchasing an additional 82,648 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of AnaptysBio in the first quarter valued at approximately $420,000. Octagon Capital Advisors LP acquired a new position in shares of AnaptysBio in the fourth quarter valued at approximately $2,570,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of AnaptysBio in the first quarter valued at approximately $1,221,000. Finally, First Light Asset Management LLC grew its position in shares of AnaptysBio by 56.4% in the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock valued at $26,500,000 after purchasing an additional 446,372 shares during the last quarter.

Analyst Upgrades and Downgrades

ANAB has been the topic of several recent analyst reports. Truist Financial lifted their target price on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. JPMorgan Chase & Co. lifted their target price on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $50.30.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.